NASDAQ:AGIO Agios Pharmaceuticals (AGIO) Stock Price, News & Analysis $27.40 -1.90 (-6.48%) Closing price 04/1/2025 04:00 PM EasternExtended Trading$27.40 0.00 (0.00%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Agios Pharmaceuticals Stock (NASDAQ:AGIO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Agios Pharmaceuticals alerts:Sign Up Key Stats Today's Range$26.66▼$29.3550-Day Range$27.40▼$35.5452-Week Range$26.66▼$62.58Volume936,690 shsAverage Volume700,705 shsMarket Capitalization$1.57 billionP/E Ratio2.42Dividend YieldN/APrice Target$56.57Consensus RatingModerate Buy Company OverviewAgios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Read More… Remove Ads Agios Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks87th Percentile Overall ScoreAGIO MarketRank™: Agios Pharmaceuticals scored higher than 87% of companies evaluated by MarketBeat, and ranked 138th out of 930 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingAgios Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 5 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageAgios Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Agios Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Agios Pharmaceuticals are expected to grow in the coming year, from ($6.85) to ($5.79) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Agios Pharmaceuticals is 2.42, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 22.58.Price to Earnings Ratio vs. SectorThe P/E ratio of Agios Pharmaceuticals is 2.42, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 23.42.Price to Book Value per Share RatioAgios Pharmaceuticals has a P/B Ratio of 1.01. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Agios Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.16% of the float of Agios Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAgios Pharmaceuticals has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Agios Pharmaceuticals has recently decreased by 13.71%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAgios Pharmaceuticals does not currently pay a dividend.Dividend GrowthAgios Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.3 / 5Environmental Score-1.11 Percentage of Shares Shorted6.16% of the float of Agios Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAgios Pharmaceuticals has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Agios Pharmaceuticals has recently decreased by 13.71%, indicating that investor sentiment is improving significantly. News and Social Media2.8 / 5News Sentiment0.97 News SentimentAgios Pharmaceuticals has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Agios Pharmaceuticals this week, compared to 5 articles on an average week. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Agios Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $90,233.00 in company stock.Percentage Held by InsidersOnly 4.93% of the stock of Agios Pharmaceuticals is held by insiders.Read more about Agios Pharmaceuticals' insider trading history. Receive AGIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Agios Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AGIO Stock News HeadlinesMOMA Therapeutics Appoints Susan Pandya, M.D., to Board of Directors and Expands Management TeamApril 1 at 9:09 AM | finance.yahoo.comIs Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) the Best Small Cap Stock to Buy Before They Explode?March 27, 2025 | msn.comElon Tax Shock?Elon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax authorities have bought a powerful new AI supercomputer, worth millions of dollars. It's the most advanced technology offered by AI giant Nvidia. And it's almost certainly going to be used to advance Elon Musk's real agenda with DOGE... the massive, rapid roll out of AI across the entire federal government.April 2, 2025 | Altimetry (Ad)Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesMarch 26, 2025 | americanbankingnews.comAuron Therapeutics Expands Leadership with Appointment of Glenn Goddard as Chief Financial OfficerMarch 20, 2025 | markets.businessinsider.comCelldex Therapeutics and Agios Pharmaceuticals to Present at March 2025 Investor ConferencesMarch 7, 2025 | theglobeandmail.comAgios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy OfficerMarch 5, 2025 | globenewswire.comAgios to Present at Upcoming Investor ConferencesMarch 4, 2025 | globenewswire.comSee More Headlines AGIO Stock Analysis - Frequently Asked Questions How have AGIO shares performed this year? Agios Pharmaceuticals' stock was trading at $32.86 on January 1st, 2025. Since then, AGIO stock has decreased by 16.6% and is now trading at $27.40. View the best growth stocks for 2025 here. How were Agios Pharmaceuticals' earnings last quarter? Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) announced its earnings results on Thursday, February, 20th. The biopharmaceutical company reported ($1.74) EPS for the quarter, missing analysts' consensus estimates of ($1.69) by $0.05. Agios Pharmaceuticals had a net margin of 1,845.92% and a negative trailing twelve-month return on equity of 2.51%. How do I buy shares of Agios Pharmaceuticals? Shares of AGIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Agios Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Agios Pharmaceuticals investors own include Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH), The RMR Group (RMR), AUO (AUOTY), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR). Company Calendar Last Earnings2/20/2025Today4/02/2025Next Earnings (Estimated)5/01/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AGIO CIK1439222 Webwww.agios.com Phone(617) 649-8600FaxN/AEmployees390Year FoundedN/APrice Target and Rating Average Stock Price Target$56.57 High Stock Price Target$75.00 Low Stock Price Target$46.00 Potential Upside/Downside+106.5%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)$11.34 Trailing P/E Ratio2.42 Forward P/E RatioN/A P/E GrowthN/ANet Income$673.72 million Net Margins1,845.92% Pretax Margin1,967.15% Return on Equity-2.51% Return on Assets-2.26% Debt Debt-to-Equity RatioN/A Current Ratio11.90 Quick Ratio11.56 Sales & Book Value Annual Sales$36.50 million Price / Sales43.01 Cash FlowN/A Price / Cash FlowN/A Book Value$27.02 per share Price / Book1.01Miscellaneous Outstanding Shares57,296,000Free Float54,471,000Market Cap$1.57 billion OptionableOptionable Beta0.90 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:AGIO) was last updated on 4/2/2025 by MarketBeat.com Staff From Our PartnersDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agios Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Agios Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.